Since these complications are likely mediated through the release of cytokines, including IL-6, IL-1, and GM-CSF, tocilizumab, an IL-6 inhibitor can be used to treat severe CRS without affecting the immune response (136, 142). The gene discussed is CSF2; the disease is congenital rubella syndrome.